Transplant/Artificial Liver
Liver Transplant - HCV
IAS 2011: Transplants Safe for HIV+ People but HCV Adds Risk
- Details
- Category: Liver & Kidney Disease
- Published on Monday, 18 July 2011 00:00
- Written by Paul Dalton
Kidney and Liver transplants can be safe and effective for people living with HIV. However hepatitis C virus (HCV) coinfection and several other factors may make such procedures more risky. 
Treatment of Recurrent Hepatitis C after Liver Transplantation
- Details
- Category: Liver Transplant - HCV
- Published on Friday, 25 February 2011 03:47
- Written by Liz Highleyman
Hepatitis C patients with advanced liver disease may benefit from interferon-based therapy before receiving a liver transplant, but side effects are common and response rates are low, according to a systematic research review described in the January 2011 issue of Alimentary Pharmacology and Therapeutics. Injected antibodies do not prevent the new liver from becoming infected, but pegyalted interferon plus ribavirin can cures recurring HCV about 30% of the time.
HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C
- Details
- Category: Decompensation & ESLD
- Published on Friday, 08 October 2010 12:46
- Written by Liz Highleyman
HIV positive liver transplant recipients with hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection did not fare worse overall than HIV negative people, according to a Spanish study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. Coinfected patients were less likely to experience organ rejection, but HCV recurrence was a leading cause of adverse outcomes.
Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease
- Details
- Category: Liver Transplant - HBV
- Published on Tuesday, 14 December 2010 12:48
- Written by Vital Therapies
An artificial liver device known as ELAD -- which runs a patient's blood through cartridges containing human liver cells -- conferred a significant survival advantage for people with acute decompensated liver disease related to chronic hepatitis B or C, according to a Chinese study presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. After 3 years, 44% of ELAD users were still alive without liver transplants, compared with 18% in the standard therapy group.
EASL 2010: PROTECT Study Finds One-third of Liver Transplant Patients Achieve Sustained Response to Pegylated Interferon plus Ribavirin
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 04 May 2010 12:56
- Written by Liz Highleyman
Combination therapy with pegylated interferon alfa-2b (PegIntron) plus ribavirin led to sustained virological response (SVR) in about 30% of hepatitis C patients after liver transplantation, according to final results from the PROTECT study reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. A similar proportion, however, were unable to complete therapy due to adverse events.
More Articles...
- EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
- Liver Transplant Do Not Impair Immune Response in HIV/HCV Coinfected Patients
- African Americans with Hepatitis C Have Worse Outcomes than White Patients after Liver Transplantation
- AASLD 2009: Study Looks at Factors Affecting Survival of HIV/HCV Coinfected Liver Transplant Recipients
Web Design and Development by